Furthermore,
Obesity: treatment tracks block fibrosis:
A team from the Nutriomic Laboratory (Sorbonne University. For example, Inserm, AP-HP) has identified a new therapeutic strategy in obesity. Nevertheless, In a preclinical study published in Cell Reports Medicinethe researchers show that the combination of two drugs. Furthermore, already approved in other indications, manages to block the fibrosis process of adipose tissue in obese mice.
With these results. In addition, scientists recall that “Preserving or restoring the proper functioning of adipose fabrics could constitute a key strategy to limit the deleterious effects of obesity”. In obesity. fibrosis contributes to metabolic complications such as insulin resistance or type 2 diabetes (DT2), and constitutes an obstacle to weight loss.
CD9 + progenitor cells associated with increased fibrosis
Before working on their combination of drugs. the research team was first interested in the cellular population of the adipose tissue of patients in obesity. obesity: treatment tracks block fibrosis The researchers had thus observed that. in these patients, the abundance of CD9 + progenitor cells was associated with increased fibrosis, alteration of glycemic control and a higher incidence of the DT2. In addition. Additionally, in patients in severe obesity (n = 88), they noted that an overabundance of these CD9 + offspring before a bariatric surgery was associated with a lower metabolic improvement at one year. These data. combined with other observations made by scientists, show that CD9 + acquire a profibrotic, inflammatory and proliferative phenotype in the event of obesity.
“These results therefore position CD9 + progenitors as leading therapeutic targets to locally improve the functioning of fatty fabric. with potential beneficial effects on overall health”, underline the authors in their study.
The team was then able to carry out more in -depth analyzes in order to identify the signaling pathways activated in CD9 +. drugs capable obesity: treatment tracks block fibrosis of inhibiting them. The researchers tested for 4 to 5 weeks in obese mice a combination of NinTedanib (anifibrosing). Cellcoxib (anti-inflammatory), two molecules already authorized in France*.
An association which has proven to be effective in significantly reducing the development of fibrosis of adipose tissue. the proliferation of CD9 +. In addition, the combination has also reduced liver steatosis, insulin resistance and permitted mice to lose weight. Note that the molecules tested separately have not given such significant results.
“The treatment has improved the structure of their adipose tissue. but also their metabolic health”, rejoice the authors who now hope “Quick translation towards clinical trials”.
*NinTedanib, under the name of OFEV specialty, is indicated in the treatment of idiopathic pulmonary fibrosis and diffuse interstitial pneumonia. Celeboxib, under the name of Celebrex specialty, is indicated in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Obesity: treatment tracks block obesity: treatment tracks block fibrosis fibrosis
Further reading: Here is the natural drink that improves memory and helps you stay Zen all summer – Valneva: EMA rises the suspension of the use of the IXCHIQ vaccine for the elderly – In the absence of American funds, the world is likely to go back more than 20 years – Mouches and Maringouins are buzzing! – Shared meal in Mouysset – Official website of the city of Tarbes.